{"id":14686,"date":"2019-12-06T09:28:07","date_gmt":"2019-12-06T14:28:07","guid":{"rendered":"https:\/\/medicarereport.org\/?p=14686"},"modified":"2019-12-06T09:28:07","modified_gmt":"2019-12-06T14:28:07","slug":"detailed-data-on-biogens-resurrected-alzheimers-drug-raise-more-questions-than-answers","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=14686","title":{"rendered":"Detailed data on Biogen\u2019s resurrected Alzheimer\u2019s drug raise more questions than answers"},"content":{"rendered":"<p>(By Rebecca Robbins and Matthew Herper for ST<em>A<\/em>T)<\/p>\n<p>SAN DIEGO \u2014 Biogen (BIIB) on Thursday presented detailed data making a case for its resurrected Alzheimer\u2019s drug, arguing that its mixed study results can be explained away by differences in whether patients got the highest dose of the medicine.\u00a0 Continue reading article <a href=\"https:\/\/www.statnews.com\/2019\/12\/05\/detailed-data-on-biogens-resurrected-alzheimers-drug-raise-more-questions-than-answers\/\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Rebecca Robbins and Matthew Herper for STAT) SAN DIEGO \u2014 Biogen (BIIB) on Thursday presented detailed data making a<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,31,15],"tags":[],"class_list":["post-14686","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-fda","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14686"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14686\/revisions"}],"predecessor-version":[{"id":14687,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14686\/revisions\/14687"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}